Protalix BioTherapeutics (PLX) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.90% |
| Dec 31, 2025 | 30.49% |
| Sep 30, 2025 | 29.11% |
| Jun 30, 2025 | 28.00% |
| Mar 31, 2025 | 28.21% |
| Dec 31, 2024 | 21.19% |
| Sep 30, 2024 | 19.70% |
| Jun 30, 2024 | 19.37% |
| Mar 31, 2024 | 20.09% |
| Dec 31, 2023 | 21.38% |
| Sep 30, 2023 | 22.85% |
| Jun 30, 2023 | 23.84% |
| Mar 31, 2023 | 15.19% |
| Dec 31, 2022 | 18.43% |
| Sep 30, 2022 | 15.08% |
| Jun 30, 2022 | 13.71% |
| Mar 31, 2022 | 35.77% |
| Dec 31, 2021 | 9.53% |
| Sep 30, 2021 | 15.03% |
| Jun 30, 2021 | 19.93% |
| Mar 31, 2021 | 40.49% |
| Dec 31, 2020 | -35.02% |
| Sep 30, 2020 | 13.43% |
| Jun 30, 2020 | 11.80% |
| Mar 31, 2020 | 12.77% |
| Dec 31, 2019 | -4.81% |
| Mar 31, 2019 | -12.26% |
| Dec 31, 2018 | -14.44% |
| Sep 30, 2018 | -23.47% |
| Jun 30, 2018 | -28.95% |
| Mar 31, 2018 | -41.34% |
| Dec 31, 2017 | -54.40% |
| Sep 30, 2017 | -49.48% |
| Jun 30, 2017 | -35.86% |
| Mar 31, 2017 | -60.36% |
| Dec 31, 2016 | 17.52% |
| Sep 30, 2016 | 2.74% |
| Jun 30, 2016 | 1.73% |
| Mar 31, 2016 | -10.85% |
| Dec 31, 2015 | 24.24% |
| Sep 30, 2015 | -80.85% |
| Jun 30, 2015 | -111.09% |